HU

Hugel, Inc.

A biopharmaceutical company developing and distributing medical aesthetic products.

145020 | KO

Overview

Corporate Details

ISIN(s):
KR7145020004
LEI:
Country:
South Korea
Address:
강원특별자치도 춘천시 동내면 거두단지1길 23 -, 춘천시

Description

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and distributes a portfolio of high-quality products, including its flagship botulinum toxin type A formulations, known commercially as Botulax and Letybo. Its product line also features a range of hyaluronic acid (HA) fillers and PDO threads. Recognized as a leader in its field, Hugel is focused on providing innovative, efficient, and proven solutions to medical professionals worldwide. The company is committed to advancing aesthetic medicine through continuous research and development to create effective and reliable treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-06-02 00:00
주식등의대량보유상황보고서(약식)
Korean 155.9 KB
2022-05-31 00:00
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Korean 89.5 KB
2022-05-19 00:00
주주총회소집결의
Korean 8.4 KB
2022-05-19 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.7 KB
2022-05-16 00:00
분기보고서 (2022.03)
Korean 1.4 MB
2022-05-11 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2022-05-11 00:00
기업설명회(IR)개최
Korean 7.1 KB
2022-05-11 00:00
기타시장안내(최대주주의의무보유관련)(최대주주의 의무보유 이행 관련)
Korean 4.1 KB
2022-05-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.6 KB
2022-05-09 00:00
주식등의대량보유상황보고서(일반)
Korean 95.9 KB
2022-05-06 00:00
[기재정정]투자판단관련주요경영사항(리도카인 함유 액상 보툴리눔 톡신 제제 "HG102" 임상1상 시험 결과)
Korean 15.8 KB
2022-05-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.5 KB
2022-05-06 00:00
주식등의대량보유상황보고서(일반)
Korean 77.2 KB
2022-05-04 00:00
결산실적공시예고
Korean 4.0 KB
2022-05-04 00:00
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all Hugel, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hugel, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hugel, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.